Vildagliptin shows diabetes benefits but raises CV concerns

05/28/2013 | MedPage Today (free registration)

A study presented at the Heart Failure Congress found type 2 diabetes patients with heart failure who took vildagliptin attained lower HbA1C levels at 16 weeks compared with those in the placebo group. However, researchers noted higher rates of cardiovascular and all-cause mortality in vildagliptin-treated patients.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA